

# Siamak Moghadam-Kia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11681526/publications.pdf>

Version: 2024-02-01

17  
papers

993  
citations

623188

14  
h-index

887659

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1453  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consumer-based activity trackers in evaluation of physical activity in myositis patients. <i>Rheumatology</i> , 2022, 61, 2951-2958.	0.9	11
2	Reliability, validity and responsiveness of physical activity monitors in patients with inflammatory myopathy. <i>Rheumatology</i> , 2021, 60, 5713-5723.	0.9	17
3	Utility of patient-reported outcomes measurement information system (PROMIS) physical function form in inflammatory myopathy. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 539-546.	1.6	17
4	Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. <i>Rheumatology</i> , 2019, 58, 1011-1015.	0.9	68
5	Myositis in clinical practice—relevance of new antibodies. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 887-901.	1.4	3
6	Anti-MDA5 Antibody Spectrum in Western World. <i>Current Rheumatology Reports</i> , 2018, 20, 78.	2.1	40
7	Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 81-87.	2.9	21
8	Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis. <i>Journal of Rheumatology</i> , 2017, 44, 319-325.	1.0	112
9	Biologics for idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2017, 29, 645-651.	2.0	9
10	A diagnostic and therapeutic approach to primary burning mouth syndrome. <i>Clinics in Dermatology</i> , 2017, 35, 453-460.	0.8	25
11	Approach to asymptomatic creatine kinase elevation. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, 37-42.	0.6	117
12	Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis. <i>Arthritis Care and Research</i> , 2016, 68, 689-694.	1.5	199
13	Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1265-1275.	1.3	27
14	Autoimmune Disease and Hair Loss. <i>Dermatologic Clinics</i> , 2013, 31, 75-91.	1.0	40
15	Prevention and treatment of systemic glucocorticoid side effects. <i>International Journal of Dermatology</i> , 2010, 49, 239-248.	0.5	218
16	Cross-sectional Analysis of a Collaborative Web-Based Database for Lupus Erythematosus-Associated Skin Lesions. <i>Archives of Dermatology</i> , 2009, 145, 255-60.	1.7	54
17	Imaging with (18)F-FDG-PET in infective endocarditis: promising role in difficult diagnosis and treatment monitoring. <i>Hellenic Journal of Nuclear Medicine</i> , 2009, 12, 165-7.	0.2	15